Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 in idiopathic pulmonary fibrosis
2017-002667-17Phase 2Unknown
- Sponsor
- Novartis
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing VAY736 with Placebo (2 arms). Primary endpoint: Change from baseline to end of treatment epoch in forced vital capacity. Status: unknown.
02
Drugs
ianalumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2017-002667-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002667-17.